Haemonetics HAE Q3 2026 Earnings Call Transcript

Image source: The Motley Fool.

Thursday, February 5, 2026 astatine 8 a.m. ET

• President and Chief Executive Officer — Christopher A. Simon

• Chief Financial Officer — James P. D'Arecca

Our remarks contiguous see forward-looking statements, and our existent results whitethorn disagree materially from the anticipated results. Factors that whitethorn origin our results to disagree see those referenced successful the harmless harbor connection successful today's release, and successful our different SEC filings. We bash not undertake immoderate work to update these forward-looking statements. And present I'd similar to crook it implicit to Christopher Simon.

Christopher Simon: Thanks, Olga. Good morning, and convey you for joining america today. We delivered a beardown 4th and we are raising our full-year revenue, earnings, and escaped currency travel guidance. Nexus and TEG delivered outsized maturation driven by sustained stock gains, innovation-based pricing, and durable end-market demand, demonstrating the spot and resilience of these halfway products and our progressively productive operating model. Third-quarter gross was $339 million, bringing year-to-date gross to $988 million. Reported gross reflects the $153 cardinal interaction of past year's portfolio transitions. Allowing for these nonrecurring items, underlying show remains strong. With integrated maturation ex CSL of 8% successful the 4th and 10% year-to-date.

Adjusted net per stock accrued 10% successful the 4th and 11% year-to-date to $1.31 and $3.67 per share, respectively, underscoring some the prime and the durability of our earnings. With that context, let's reappraisal our businesses successful much detail. Hospital gross was $144 cardinal successful the 4th and $429 cardinal year-to-date, down 1% successful the 4th and up 2% year-to-date organically. As beardown show successful Blood Management Technologies offset softness successful interventional technologies. Blood absorption technologies delivered coagulated growth, up 8% successful the 4th and 11% year-to-date, driven by sustained double-digit maturation successful hemostasis management. Momentum was fueled by TEG 6s disposable income and accelerated adoption of the planetary heparinase neutralization cartridge, which continues to accelerate relationship conversions and penetration.

We person important runway to upgrade bequest TEG 5,000 systems, summation TEG 6s instrumentality income and utilization, and grow stock wrong existent indications. The motorboat of the HN cartridge successful EMEA and Japan further strengthens our planetary enactment and adds planetary maturation vectors to the $400 cardinal positive serviceable market. Growth elsewhere successful BMT was modest, with transfusion absorption gains mostly offset by a diminution successful compartment salvage driven by a pugnacious comp pursuing past year's lawsuit migration to higher-margin exertion offerings. Interventional exertion gross declined 12% successful the 4th and 8% year-to-date, driven chiefly by softness successful esophageal cooling amid accelerating PFA adoption and OEM-related headwinds successful sensor-guided technologies, which unneurotic accounted for astir of the year-over-year quarterly decline.